-
work shows that antigen-specific and MHC-restricted gammadelta T cells can be generated in vitro and that MART-1-specific gammadelta T cells can also be found and cloned from the naive repertoire
-
Expression of HMB45, MelanA and SOX10 is evident but exceedingly rare in non-small cell lung cancer cases
-
Melan-A-stained slides shows definitive invasion.
-
Report automated quantification of proliferation with automated hot-spot selection in phosphohistone H3/MART1 dual-stained stage I/II melanoma.
-
Suggest MelanA-negative spindle-cell associated melanoma constitutes a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin.
-
Inhibin alpha-subunit, Melan A and MNF116 were not sensitive for pheochromocytomas.
-
the presence of antibody and T-cell immune responses directed against the melanocyte-differentiation-antigens MART-1 (Melan-A), tyrosinase and gp100 in patients with melanoma-associated leucoderma, as compared to patients with vitiligo.
-
Knockdown of T-bet expression in Mart-127-35 -specific T-cell-receptor-engineered human CD4(+) CD25(-) and CD8(+) T cells attenuates effector function.
-
Melan-A was useful to confirm the diagnosis of lentigo maligna in early lesions and to differentiate these from chronically sun-damaged skin.
-
Misinitiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells.
-
Comprehensive characterization of the marginal and joint distributions for S100, HMB-45, and Melan-A across a large series of cutaneous melanomas revealed diversity of expression across this group of antigens.
-
melan A (A103) is not expressed in mesotheliomas
-
Report diagnostic role of immunohistochemical staining for Melan-A in evaluating primary melanoma and, specifically, in situ melanoma cases.
-
In this study, production of the C terminus of the Melan-A(26-35) epitope requires cleavage within a hydrophobic stretch, after V35. Hence, the standard proteasome is the only proteasome able to produce the C terminus of this epitope.
-
naturally occurring MART-1 melanoma antigen can be taken-up from dying melanoma cells into DC or MAK and both cell types can induce specific CD8(+) T cell cross-presentation thereafter.
-
The presence of circulating T cells responding to Melan-A or NY-ESO-1 had strong independent prognostic impact on survival in advanced melanoma.
-
The modified melan-A long peptides (not their wild-type counterparts) give rise to highly sustained cross-presentation capacity by monocyte-derived dendritic cells and could be used as tumor vaccines for treatment of melanoma patients.
-
Aberrant expression of Melan-A and MART-1 in AFX and undifferentiated pleomorphic sarcoma of the skin represents an important diagnostic pitfall with potential for misdiagnosis as melanoma.
-
MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro.
-
we established several CD4 T-cell clones that recognized a peptide that is embedded within Melan-A/MART-121-50, in a HLA-DPB1*0501 restricted manner